Literature DB >> 17392934

Using problem solving therapy in general practice.

David Pierce1, Jane Gunn.   

Abstract

BACKGROUND: In Australia, mild and moderate depression is predominantly treated by general practitioners. Many of these patients prefer a nondrug therapeutic approach. Problem solving therapy (PST) is an evidence based psychological treatment that can be provided to such patients by GPs.
OBJECTIVE: This article aims to explain what PST is, how PST skills may be developed, and how specific difficulties using PST may be addressed. DISCUSSION: Problem solving therapy consists of a series of sequential structured stages. While many GPs use elements of the PST approach, few use its structured format. In this article the specific stages of PST are described in detail. This is followed by a discussion of ways GPs can learn more about developing PST skills from their existing problem solving skills. Finally, difficulties observed using PST are described in combination with potential responses to these difficulties.

Entities:  

Mesh:

Year:  2007        PMID: 17392934

Source DB:  PubMed          Journal:  Aust Fam Physician        ISSN: 0300-8495


  3 in total

1.  Lay Health Workers' Experience of Delivering a Problem Solving Therapy Intervention for Common Mental Disorders Among People Living with HIV: A Qualitative Study from Zimbabwe.

Authors:  Dixon Chibanda; Frances Cowan; Ruth Verhey; Debra Machando; Melanie Abas; Crick Lund
Journal:  Community Ment Health J       Date:  2016-05-24

2.  A randomized controlled trial of problem-solving therapy compared to cognitive therapy for the treatment of insomnia in adults.

Authors:  Melissa Pech; Richard O'Kearney
Journal:  Sleep       Date:  2013-05-01       Impact factor: 5.849

3.  General practitioners' attitudes towards patients with poorly controlled type 2 diabetes: a qualitative study.

Authors:  Anja Wollny; Michael Pentzek; Oliver Rudolf Herber; Heinz-Harald Abholz; Jürgen In der Schmitten; Andrea Icks; Stefan Wilm; Elisabeth Gummersbach
Journal:  BMC Fam Pract       Date:  2018-05-02       Impact factor: 2.497

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.